NATCO Pharma Limited
NSE: NATCOPHARM BSE: NATCOPHARM
NSE
835.90
0.00 (0.00%)
Prev Close
835.9
Open Price
835.9
Volume
208,774
Today Low / High
816.25 / 848.95
52 WK Low / High
726.8 / 1341
Range
794 - 878
BSE
835.45
-7.05 (2.70%)
Prev Close
835.45
Open Price
835.45
Volume
14,941
Today Low / High
817.7 / 849.1
52 WK Low / High
660.05 / 1340.45
Range
794 - 877
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 835.9 (target range: 794 - 878), reflecting a change of -1.1368683772162E-13 (-1.3600530891448E-14%). On the BSE, it is listed at 835.45 (target range: 794 - 877), showing a change of -7.05 (2.6982%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
01 Feb
835.90
-0.71%
30 Jan
810.00
3.20%
29 Jan
821.80
-1.05%
28 Jan
820.05
-0.19%
27 Jan
840.00
-3.07%
23 Jan
835.00
-0.37%
22 Jan
844.95
-1.21%
21 Jan
819.95
2.41%
20 Jan
851.20
-3.34%
19 Jan
861.00
-1.77%
16 Jan
892.00
-3.65%
14 Jan
875.00
1.94%
13 Jan
866.00
0.67%
12 Jan
890.00
-3.61%
09 Jan
913.20
-2.52%
08 Jan
950.75
-4.32%
07 Jan
930.40
1.69%
06 Jan
909.85
1.76%
05 Jan
893.85
1.37%
NATCO Pharma Limited Graph
NATCO Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for NATCO Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 835.90, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 835.45 | 843.80 | 759.42 - 928.18 |
| 852.16 | 681.73 - 1,022.59 | ||
| 860.51 | 602.36 - 1,118.67 | ||
| Bearish Scenario | 835.45 | 827.10 | 744.39 - 909.81 |
| 818.74 | 654.99 - 982.49 | ||
| 810.39 | 567.27 - 1,053.50 |
Overview of NATCO Pharma Limited
ISIN
INE987B01026
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,526,488
Market Cap
149,717,940,333
Last Dividend
5
Official Website
IPO Date
1996-01-01
DCF Diff
-1,183.99
DCF
2,067
Financial Ratios Every Investor Needs
Stock Dividend of NATCOPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-11-20 | November 20, 25 | 1.5 | 1.5 | 2025-11-20 | 2025-11-28 | |
| 2025-08-19 | August 19, 25 | 2 | 2 | 2025-08-19 | 2025-08-26 | |
| 2025-02-18 | February 18, 25 | 1.5 | 1.5 | 2025-02-18 | 2025-03-14 | |
| 2024-11-27 | November 27, 24 | 1.5 | 1.5 | 2024-11-27 | 2024-12-04 | |
| 2024-08-23 | August 23, 24 | 3 | 3 | 2024-08-23 | 2024-09-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,431.90 Cr | 727.40 Cr | 3,704.50 Cr | 0.8359 | 104.00 Cr | 0.00 Cr | 3,000.30 Cr | 1,885.40 Cr | 105.26 | 2,144.20 Cr | 0.4254 |
| 2024-03-31 | 4,002.00 Cr | 748.70 Cr | 3,253.30 Cr | 0.8129 | 121.10 Cr | 0.00 Cr | 2,596.20 Cr | 1,388.30 Cr | 77.34 | 1,750.60 Cr | 0.3469 |
| 2023-03-31 | 2,708.50 Cr | 654.40 Cr | 2,054.10 Cr | 0.7584 | 89.20 Cr | 0.00 Cr | 1,491.60 Cr | 715.30 Cr | 39.18 | 966.90 Cr | 0.2641 |
| 2022-03-31 | 1,946.20 Cr | 584.50 Cr | 1,361.70 Cr | 0.6997 | 168.20 Cr | 467.90 Cr | 693.00 Cr | 170.00 Cr | 9.32 | 260.00 Cr | 0.0873 |
| 2021-03-31 | 2,056.10 Cr | 531.80 Cr | 1,524.30 Cr | 0.7414 | 142.50 Cr | 429.60 Cr | 931.10 Cr | 440.90 Cr | 24.20 | 606.60 Cr | 0.2144 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,176.00 Cr | 8,630.80 Cr | 1,018.50 Cr | 7,607.0000 Cr | 279.40 Cr | -1,896.60 Cr | 765.80 Cr | 2,657.30 Cr | 0.00 Cr | 0.00 Cr | 335.10 Cr | 943.5000 Cr |
| 2024-03-31 | 70.40 Cr | 6,906.30 Cr | 1,053.20 Cr | 5,853.1000 Cr | 386.10 Cr | 315.70 Cr | 791.70 Cr | 2,435.00 Cr | 0.00 Cr | 4.00 Cr | 97.30 Cr | 972.8000 Cr |
| 2023-03-31 | 131.90 Cr | 5,657.40 Cr | -3,480.00 Cr | 4,873.8000 Cr | 176.10 Cr | 34.80 Cr | 808.90 Cr | 2,303.40 Cr | 112.90 Cr | 1.70 Cr | -925.90 Cr | 683.1000 Cr |
| 2022-03-31 | 111.10 Cr | 5,109.10 Cr | 845.50 Cr | 4,263.6000 Cr | 432.00 Cr | 320.90 Cr | 862.00 Cr | 2,308.40 Cr | 87.70 Cr | 1.30 Cr | 108.90 Cr | 710.4000 Cr |
| 2021-03-31 | 25.80 Cr | 4,791.90 Cr | 668.50 Cr | 4,121.6000 Cr | 283.90 Cr | 258.10 Cr | 910.40 Cr | 2,237.20 Cr | 1.30 Cr | 1.10 Cr | -625.00 Cr | 525.6000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,696.8000 Cr | -1,414.5000 Cr | -210.7000 Cr | 1,428.0000 Cr | 49.6000 Cr | 120.0000 Cr | -511.6000 Cr | 1,885.4000 Cr | -89.2000 Cr | -107.8000 Cr | -65.3000 Cr |
| 2024-03-31 | 1,211.6000 Cr | -1,032.7000 Cr | -246.9000 Cr | 872.2000 Cr | -61.5000 Cr | 70.4000 Cr | -339.4000 Cr | 1,388.3000 Cr | 197.8000 Cr | -170.8000 Cr | 42.4000 Cr |
| 2023-03-31 | 849.1000 Cr | -477.1000 Cr | -363.0000 Cr | 643.5000 Cr | 20.8000 Cr | 131.9000 Cr | -205.6000 Cr | 861.9000 Cr | -239.0000 Cr | -100.4000 Cr | 19.1000 Cr |
| 2022-03-31 | 46.5000 Cr | -5.3000 Cr | 34.8000 Cr | -196.2000 Cr | 85.3000 Cr | 111.1000 Cr | -242.7000 Cr | 202.2000 Cr | -2.4000 Cr | -82.2000 Cr | 56.4000 Cr |
| 2021-03-31 | 298.8000 Cr | -103.3000 Cr | -185.7000 Cr | 44.2000 Cr | 6.0000 Cr | 25.8000 Cr | -254.6000 Cr | 579.6000 Cr | -48.4000 Cr | -113.9000 Cr | -240.2000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1,363.00 Cr | 169.70 Cr | 1,193.30 Cr | 0.8755 | 526.80 Cr | 518.40 Cr | 28.94 | 679.20 Cr | 0.3803 |
| 2025-06-30 | 1,328.90 Cr | 233.00 Cr | 1,095.90 Cr | 0.8247 | 513.40 Cr | 480.70 Cr | 26.84 | 632.70 Cr | 0.3617 |
| 2025-03-31 | 1,223.40 Cr | 286.80 Cr | 936.60 Cr | 0.7656 | 667.50 Cr | 406.60 Cr | 22.70 | 499.70 Cr | 0.3324 |
| 2024-12-31 | 474.80 Cr | 82.80 Cr | 392.00 Cr | 0.8256 | 250.40 Cr | 133.00 Cr | 7.43 | 36.80 Cr | 0.2801 |
| 2024-09-30 | 1,371.10 Cr | 177.60 Cr | 1,193.50 Cr | 0.8705 | 1,042.00 Cr | 677.30 Cr | 37.81 | 803.45 Cr | 0.4940 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 103.50 Cr | 3,973.30 Cr | 4,076.80 Cr | 1,729.10 Cr | 818.00 Cr | 6,966.70 Cr | 2,692.30 Cr | 10,430.10 Cr | 1,775.90 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2,496.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,612.30 Cr |
| 2025-03-31 | 2,176.00 Cr | 2,687.60 Cr | 2,496.80 Cr | 1,256.00 Cr | 765.80 Cr | 5,270.00 Cr | 2,657.30 Cr | 8,630.80 Cr | 1,018.50 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 2,463.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -7,156.80 Cr |
| 2024-09-30 | 104.60 Cr | 2,358.80 Cr | 2,463.40 Cr | 1,445.80 Cr | 774.60 Cr | 5,001.50 Cr | 2,538.20 Cr | 8,244.70 Cr | 1,087.90 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 480.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 406.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 133.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 677.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 668.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-11-26 | November 26, 15 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,595.30 | ₹3,827,659,077,641.00 | ₹1,849,710.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,031.00 | ₹1,601,041,005,980.00 | ₹96,030.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,960.80 | ₹1,340,514,698,752.00 | ₹50,076.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,200.00 | ₹999,081,828,000.00 | ₹380,220.00 |
| Lupin Limited | LUPIN | ₹2,152.80 | ₹983,396,887,200.00 | ₹153,290.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹885.30 | ₹890,818,951,347.00 | ₹140,316.00 |
| Mankind Pharma Limited | MANKIND | ₹2,124.00 | ₹876,797,972,928.00 | ₹287,261.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,182.80 | ₹686,972,159,684.00 | ₹574,635.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,620.00 | ₹671,955,300,000.00 | ₹20,830.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,960.90 | ₹553,367,566,368.00 | ₹308,665.00 |
| Laurus Labs Limited | LAURUSLABS | ₹940.90 | ₹507,951,058,004.00 | ₹1,196,464.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,427.70 | ₹362,213,512,039.00 | ₹38,416.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,782.00 | ₹347,570,905,968.00 | ₹27,274.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,880.70 | ₹301,730,104,500.00 | ₹48,837.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,485.00 | ₹281,515,221,900.00 | ₹56,011.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,382.20 | ₹224,596,675,992.00 | ₹241,327.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,615.00 | ₹215,375,000,000.00 | ₹3,296.00 |
| Eris Lifesciences Limited | ERIS | ₹1,386.10 | ₹188,810,232,615.00 | ₹11,485.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹53,893.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹777.60 | ₹152,847,485,222.00 | ₹26,375.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹953.75 | ₹151,045,147,155.00 | ₹22,670.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹835.90 | ₹149,717,940,333.00 | ₹208,764.00 |
| Cohance Lifesciences Limited | COHANCE | ₹367.50 | ₹140,593,423,950.00 | ₹169,039.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,802.10 | ₹136,980,677,362.00 | ₹25,851.00 |
| Granules India Limited | GRANULES | ₹557.20 | ₹135,215,008,555.00 | ₹273,857.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹937.60 | ₹115,025,705,600.00 | ₹28,984.00 |
| Viyash Scientific Limited | VIYASH | ₹203.61 | ₹88,815,813,868.00 | ₹245,657.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,303.00 | ₹88,026,522,746.00 | ₹4,739.00 |
| Strides Pharma Science Limited | STAR | ₹877.00 | ₹80,835,470,178.00 | ₹379,638.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹756.05 | ₹68,533,886,629.00 | ₹69,500.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.00 | ₹68,283,517,868.00 | ₹92,422.00 |
| FDC Limited | FDC | ₹376.70 | ₹61,330,558,643.00 | ₹31,298.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹288.95 | ₹56,513,365,733.00 | ₹4,776,413.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹126.08 | ₹40,915,681,815.00 | ₹7,990,855.00 |
| Innova Captab Limited | INNOVACAP | ₹695.00 | ₹39,771,325,655.00 | ₹12,945.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.85 | ₹35,615,296,865.00 | ₹58,760.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹386.75 | ₹35,298,672,500.00 | ₹63,468.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹693.00 | ₹35,148,339,765.00 | ₹14,366.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,007.90 | ₹33,208,688,219.00 | ₹3,827.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹303.90 | ₹30,475,853,573.00 | ₹29,080.00 |
| Suven Life Sciences Limited | SUVEN | ₹132.81 | ₹30,210,821,940.00 | ₹346,948.00 |
Key Executives
President of Technical Affairs & Whole Time Director
Donthineni Linga Rao
Gender: Not Specified
Year Born: 1952
Vice President of Marketing & Sales - Domestic
James Rajakumar
Gender: Not Specified
Year Born:
Senior Vice President of HR & Organisational Development
A. Lakshminarayana
Gender: male
Year Born: 1963
Executive Vice President Finance & Accounts
Amit Parekh
Gender: male
Year Born:
Company Secretary & Compliance Officer
Chekuri Venkat Ramesh
Gender: male
Year Born:
Executive VP of Corporate Engineering Services & Whole Time Director
Potluri Sivaramakrishna Prasad
Gender: male
Year Born: 1958
Chief Executive Officer & Vice Chairman
Rajeev Nannapaneni
Gender: male
Year Born: 1977
Chief Financial Officer
S. V. V. N. Appa Rao
Gender: male
Year Born:
MD & Chairman
Venkaiah Chowdary Nannapaneni MS.
Gender: male
Year Born: 1945
VP & Head of Operations
Nadella Malleswara Rao
Gender: Not Specified
Year Born:
Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management
N. Sadasiva Rao
Gender: Not Specified
Year Born:
FAQs about NATCO Pharma Limited
Who is the CEO of the company?
The CEO is Rajeev Nannapaneni.
What is the current market price of the stock?
The current price is ₹835.90.
What is the 52-week price range?
The range is ₹726.8-1341.
What is the market capitalization of the company?
The market capitalization is ₹14,971.79 crores.
What is the dividend yield?
The dividend yield is 0.60%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 9.73.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of NATCO Pharma Limited (ISIN: INE987B01026) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹14,971.79 crores and an average daily volume of 1,526,488 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.